ZURA BIO LIMITED Increase (Decrease) in Accounts Payable and Accrued Liabilities
ZURA BIO LIMITED (ZURA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $3.74 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- ZURA BIO LIMITED increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.23M.
- ZURA BIO LIMITED increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$1.22M, a 177.39% decline year-over-year.
- ZURA BIO LIMITED increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$3.08M, a 242.36% decline year-over-year.
- ZURA BIO LIMITED increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $919.87K, a 59.33% decline year-over-year.
- ZURA BIO LIMITED increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$2.16M, a 151.33% decline from fiscal 2024.
- ZURA BIO LIMITED increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $4.21M, a 29.10% decline from fiscal 2023.
- ZURA BIO LIMITED increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $5.94M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 2 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 5 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 8 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 11 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.74K 10-Q · filed 2026-08-11 | -$3.08M derived: sum of 3 quarters · filed 2026-08-11 | -$2.16M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2026-03-31 | -$1.22M 10-Q · filed 2026-05-07 | -$4.30M derived: sum of 2 quarters · filed 2026-05-07 | -$3.38M derived: sum of 3 quarters · filed 2026-05-07 | -$4.96M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.16M derived: sum of 2 quarters · filed 2026-03-19 | -$3.74M derived: sum of 3 quarters · filed 2026-08-11 | -$2.16M 10-K · filed 2026-03-19 | |||||
| 2025-09-30 | $919.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$660.00K derived: sum of 2 quarters · filed 2026-08-11 | $919.00K 10-Q · filed 2025-11-13 | $3.08M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-06-30 | -$1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$872.00 10-Q · filed 2026-08-11 | -$872.00K 10-Q · filed 2025-08-14 | $2.16M derived: sum of 3 quarters · filed 2026-08-11 | $4.43M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $1.58M 10-Q · filed 2026-05-07 | $3.74M derived: sum of 2 quarters · filed 2026-05-07 | $6.01M derived: sum of 3 quarters · filed 2026-05-07 | $6.40M derived: sum of 4 quarters · filed 2026-05-07 | |||||
| 2024-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.43M derived: sum of 2 quarters · filed 2026-03-19 | $4.82M derived: sum of 3 quarters · filed 2026-03-19 | $4.21M 10-K · filed 2026-03-19 | |||||
| 2024-09-30 | $2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.66M derived: sum of 2 quarters · filed 2025-11-13 | $2.05M 10-Q · filed 2025-11-13 | $5.36M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $394.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$213.00K 10-Q · filed 2025-08-14 | $3.10M derived: sum of 3 quarters · filed 2025-08-14 | $6.54M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | -$607.00K 10-Q · filed 2025-05-08 | $2.71M derived: sum of 2 quarters · filed 2025-05-08 | $6.15M derived: sum of 3 quarters · filed 2025-05-08 | $4.88M derived: sum of 4 quarters · filed 2025-05-08 | |||||
| 2023-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $6.76M derived: sum of 2 quarters · filed 2025-03-25 | $5.49M derived: sum of 3 quarters · filed 2025-03-25 | $5.94M 10-K · filed 2025-03-25 | |||||
| 2023-09-30 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.18M derived: sum of 2 quarters · filed 2024-11-07 | $2.63M 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | -$1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$813.00K 10-Q · filed 2024-08-13 | -$406.00K 10-Q · filed 2023-08-14 | ||||||
| 2023-03-31 | $455.00K 10-Q · filed 2024-05-09 | ||||||||
| 2022-12-31 | $3.75M 10-K · filed 2024-03-28 | ||||||||
| 2022-09-30 | $637.00K 10-Q · filed 2023-11-13 | ||||||||
| 2022-06-30 | $371.00K 10-Q · filed 2023-08-14 | ||||||||
| 2022-03-31 | $39.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |